Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 249

1.

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.

Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gómez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK.

Breast Cancer Res. 2014 Jan 22;16(1):R7. doi: 10.1186/bcr3599.

2.

Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.

Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA; Translational Breast Cancer Research Consortium (TBCRC 011).

Clin Cancer Res. 2013 Oct 1;19(19):5505-12. doi: 10.1158/1078-0432.CCR-12-3327. Epub 2013 Aug 21.

3.

Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.

Zhu Y, Liu C, Armstrong C, Lou W, Sandher A, Gao AC.

Clin Cancer Res. 2015 Sep 15;21(18):4133-42. doi: 10.1158/1078-0432.CCR-15-0269. Epub 2015 May 20.

4.

Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.

Guerrero J, Alfaro IE, Gómez F, Protter AA, Bernales S.

Prostate. 2013 Sep;73(12):1291-305. doi: 10.1002/pros.22674. Epub 2013 Jun 13.

PMID:
23765603
5.

Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.

Ciupek A, Rechoum Y, Gu G, Gelsomino L, Beyer AR, Brusco L, Covington KR, Tsimelzon A, Fuqua SA.

Breast Cancer Res Treat. 2015 Nov;154(2):225-37. doi: 10.1007/s10549-015-3609-7. Epub 2015 Oct 20.

PMID:
26487496
6.

Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator.

Poutiainen PK, Huhtala T, Jääskeläinen T, Petsalo A, Küblbeck J, Kaikkonen S, Palvimo JJ, Raunio H, Närvänen A, Peräkylä M, Juvonen RO, Honkakoski P, Laatikainen R, Pulkkinen JT.

Mol Cell Endocrinol. 2014 Apr 25;387(1-2):8-18. doi: 10.1016/j.mce.2014.02.008. Epub 2014 Feb 22.

PMID:
24565895
7.
8.

The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation.

Garay JP, Karakas B, Abukhdeir AM, Cosgrove DP, Gustin JP, Higgins MJ, Konishi H, Konishi Y, Lauring J, Mohseni M, Wang GM, Jelovac D, Weeraratna A, Sherman Baust CA, Morin PJ, Toubaji A, Meeker A, De Marzo AM, Lewis G, Subhawong A, Argani P, Park BH.

Breast Cancer Res. 2012 Feb 9;14(1):R27.

9.

Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo.

Barton VN, D'Amato NC, Gordon MA, Lind HT, Spoelstra NS, Babbs BL, Heinz RE, Elias A, Jedlicka P, Jacobsen BM, Richer JK.

Mol Cancer Ther. 2015 Mar;14(3):769-78. doi: 10.1158/1535-7163.MCT-14-0926. Epub 2015 Feb 23.

10.

Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-alpha-positive and -negative breast cancer cells.

Lin HY, Sun M, Lin C, Tang HY, London D, Shih A, Davis FB, Davis PJ.

J Steroid Biochem Mol Biol. 2009 Feb;113(3-5):182-8. doi: 10.1016/j.jsbmb.2008.12.010. Epub 2008 Dec 30.

PMID:
19159686
11.

Targeting androgen receptor in estrogen receptor-negative breast cancer.

Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, Rimm DL, Liu XS, Brown M.

Cancer Cell. 2011 Jul 12;20(1):119-31. doi: 10.1016/j.ccr.2011.05.026.

12.

Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor.

Weng SC, Kashida Y, Kulp SK, Wang D, Brueggemeier RW, Shapiro CL, Chen CS.

Mol Cancer Ther. 2008 Apr;7(4):800-8. doi: 10.1158/1535-7163.MCT-07-0434.

13.

Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer.

Hilborn E, Gacic J, Fornander T, Nordenskjöld B, Stål O, Jansson A.

Br J Cancer. 2016 Feb 2;114(3):248-55. doi: 10.1038/bjc.2015.464. Epub 2016 Jan 7.

PMID:
26742006
14.

Targeting the androgen receptor in prostate cancer.

Culig Z.

Expert Opin Pharmacother. 2014 Jul;15(10):1427-37. doi: 10.1517/14656566.2014.915313. Epub 2014 Jun 2. Review.

PMID:
24890318
15.

Revising the role of the androgen receptor in breast cancer.

Fioretti FM, Sita-Lumsden A, Bevan CL, Brooke GN.

J Mol Endocrinol. 2014 Jun;52(3):R257-65. doi: 10.1530/JME-14-0030. Epub 2014 Apr 16. Review.

16.

Antiandrogenic actions of medroxyprogesterone acetate on epithelial cells within normal human breast tissues cultured ex vivo.

Ochnik AM, Moore NL, Jankovic-Karasoulos T, Bianco-Miotto T, Ryan NK, Thomas MR, Birrell SN, Butler LM, Tilley WD, Hickey TE.

Menopause. 2014 Jan;21(1):79-88. doi: 10.1097/GME.0b013e3182936ef4.

PMID:
23715406
17.

Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling.

Narayanan R, Ahn S, Cheney MD, Yepuru M, Miller DD, Steiner MS, Dalton JT.

PLoS One. 2014 Jul 29;9(7):e103202. doi: 10.1371/journal.pone.0103202. eCollection 2014.

18.

Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.

Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington KR, Tsimelzon A, Wang T, Hilsenbeck SG, Chamness GC, Andò S, Fuqua SA.

J Natl Cancer Inst. 2011 Apr 6;103(7):538-52. doi: 10.1093/jnci/djr058. Epub 2011 Mar 29.

19.

Targeted androgen pathway suppression in localized prostate cancer: a pilot study.

Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D, Matsumoto AM, True LD, Vessella R, Penning T, Hunter Merrill R, Gulati R, Montgomery B.

J Clin Oncol. 2014 Jan 20;32(3):229-37. doi: 10.1200/JCO.2012.48.6431. Epub 2013 Dec 9.

20.

ARN-509: a novel antiandrogen for prostate cancer treatment.

Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH.

Cancer Res. 2012 Mar 15;72(6):1494-503. doi: 10.1158/0008-5472.CAN-11-3948. Epub 2012 Jan 20.

Items per page

Supplemental Content

Write to the Help Desk